IJACT, Volume 2, Issue 5, 2024 ISSN: 2995-5378
http://medicaljournals.eu/index.php/IJACT

INTERNATIONAL JOURNAL OF ALTERNATIVE AND CONTEMPORARY THERAPY

Evaluating Novel Anticoagulant and Antiplatelet Drugs for Thromboembolic Illness Prevention and Treatment

Abdukahorova Rukhshona Nodirovna, Makhmudova Marjona Maksudovna
Student of the Faculty of Medicine, Samarkand Medical University

Dr. Imran Aslam, PhD
Department of Pharmacology, Samarkand State Medical University

Abdurakhmonova Zamira Ergashboevna
Assistant at the Department of Pharmacology, Samarkand Medical University

Abstract: Infarction of the deep veins (DVT) and pulmonary embolism, and stroke are examples of thromboembolic illnesses that are principal causes of mortality and morbidity on a global scale. The development of novel anticoagulant and antiplatelet medications has fundamentally changed the prevention and treatment of these illnesses. This article evaluates the safety and efficacy of these cutting-edge therapeutic treatments, with a focus on direct oral anticoagulants (DOACs) and new antiplatelet drugs. An examination of recent clinical trials and real-world data provides a comprehensive assessment of their benefits and drawbacks.

Keywords: DOACs, anticoagulant, antiplatelet, thromboembolic diseases, stroke prevention, venous thromboembolism, atrial fibrillation, major bleeding, ticagrelor, prasugrel, clinical efficacy, safety profile.

Introduction:

Thromboembolic illnesses provide a major challenge in therapeutic practice due to their severe consequences and high prevalence. In the past, aspirin and clopidogrel were commonly used as antiplatelet medications, while vitamin K antagonists (VKAs) and heparins were the primary treatments for anticoagulation therapy. However, these medications do possess certain disadvantages, such as irregular pharmacokinetics, dietary restrictions, and risks of bleeding. The introduction of Direct Oral Anticoagulants (DOACs) and novel antiplatelet medicines has provided safer and more effective alternatives.

Mechanism of Action

Anticoagulants

Direct oral anticoagulants (DOACs) include dabigatran, rivaroxaban, apixaban, and edoxaban. These medications function by obstructing key enzymes involved in the cascade of coagulation. Direct thrombin inhibitor dabigatran inhibits thrombin; factor Xa is blocked by rivaroxaban, apixaban, and edoxaban. These drugs have predictable pharmacokinetics, result in fewer drug interactions, and don't require periodic monitoring.

Antiplatelet Agents

Ticagrelor and prasugrel, two more recent antiplatelet medications, inhibit the P2Y12 receptor on platelets with greater efficacy compared to clopidogrel. Acute coronary syndrome (ACS) and patients undergoing percutaneous coronary intervention (PCI) benefit from the more potent platelet inhibition and quicker onset of effect of these medications.

Clinical Efficacy

Anticoagulants

DOACs have been shown to be effective in preventing stroke in patients with atrial fibrillation (AF) and treating venous thromboembolism (VTE) in numerous randomised controlled trials (RCTs). With an equivalent risk of haemorrhage, dabigatran was found to be more effective than warfarin in preventing stroke and systemic embolism, according to the RE-LY trial. With lower rates of severe bleeding, the ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 studies confirmed the non-inferiority or superiority of rivaroxaban, apixaban, and edoxaban, respectively, over warfarin.

Antiplatelet Agents

The PLATO study found that, in contrast to clopidogrel, in patients with ACS, ticagrelor substantially decreased the risk of cardiovascular mortality, myocardial infarction (MI), and stroke. Similarly, prasugrel, despite its higher risk of bleeding, was found to minimise ischemic events more effectively than clopidogrel in the TRITON-TIMI 38 study.

Literature review:

The discovery of new anticoagulant and antiplatelet medications has significantly improved the treatment and prevention of thromboembolic diseases. These novel drugs have better safety profiles, less drug interactions, and more predictable pharmacokinetics than older antiplatelet pharmaceuticals and established treatments like vitamin K antagonists (VKAs). This review of the literature discusses new antiplatelet medications and direct oral anticoagulants (DOACs), summarizing recent research on the efficacy and safety of these cutting-edge therapeutic alternatives.

Direct Oral Anticoagulants (DOACs)

Dabigatran

Dabigatran, a direct thrombin inhibitor, was the initial DOAC to receive clinical approval. In the seminal RE-LY trial, patients with non-valvular atrial fibrillation were compared between dabigatran and warfarin. In contrast to warfarin, dabigatran (150 mg twice daily) demonstrated superior efficacy in preventing stroke and systemic embolism, with a reduced risk of cerebral haemorrhage but comparable severity of haemorrhage. Additional clinical trials and meta-analyses have validated the preventive effect of dabigatran in patients with atrial fibrillation.

Rivaroxaban

Rivaroxaban, an inhibitor of direct factor Xa, was evaluated in ROCKET AF. Rivaroxaban exhibited similar efficacy to warfarin in the prevention of stroke and systemic embolism among patients with non-valvular atrial fibrillation, as reported by Patel et al. (2011). The trial also found that rivaroxaban reduced intracranial and lethal haemorrhage more than warfarin. Rivaroxaban's efficacy and safety in varied patient populations have been confirmed by real-world investigations.

Apixaban

Another direct factor Xa inhibitor, apixaban, is safe and effective. Granger et al. (2011) found that apixaban prevented stroke or systemic embolism in patients with atrial fibrillation compared to warfarin, with decreased significant bleeding and mortality. Clinicians choose apixaban due to its consistent performance throughout research.

Edoxaban

Edoxaban prevented strokes in atrial fibrillation patients comparably to warfarin in the ENGAGE AF-TIMI 48 study. Giugliano et al. (2013) found that edoxaban reduced major bleeding risk more than warfarin. Post-marketing surveillance and real-world evidence support Edoxaban's safety and efficacy.

Novel Antiplatelet Agents

Ticagrelor

Reversible P2Y12 receptor antagonist ticagrelor has been extensively explored in acute coronary syndrome patients. The PLATO trial demonstrated that ticagrelor decreased the risk of cardiovascular death and myocardial infarction., and stroke in ACS patients better than clopidogrel. Wallentin et al. (2009) found that ticagrelor increased non-CABG-related significant bleeding but improved cardiovascular protection. The benefits of ticagrelor have been confirmed in many therapeutic situations, including coronary percutaneous intervention.

Prasugrel

In the TRITON-TIMI 38 study, prasugrel outperformed clopidogrel. Prasugrel reduced ischemic episodes in ACS patients having PCI, but increased major bleeding risk, according to Wiviott et al. (2007). Prasugrel's improved antiplatelet actions benefit high-risk patients, although cautious patient selection reduces bleeding risks.

Relevance:

Thromboembolic illnesses like DVT, PE, and stroke are global health issues. Novel DOACs and antiplatelet drugs have greatly improved prevention and treatment. Dabigatran, rivaroxaban, apixaban, edoxaban, ticagrelor, and prasugrel have significant advantages over vitamin K antagonists (VKAs) and previous antiplatelet medicines.

Purpose of Study:

New anticoagulants and antiplatelets are tested for their efficacy and safety in preventing and treating thromboembolic disorders such DVT, PE, and stroke. It compares these drugs to standard therapy for efficacy, safety, and practicality. Real-world performance is examined to inform therapeutic practice with evidence-based insights. The goal is to enhance patient outcomes and develop research directions.

Methods:

A systematic review and meta-analysis of observational studies, RCTs, and real-world evidence was conducted to evaluate the safety and efficacy of novel DOACs and antiplatelet medications. A full PubMed, Cochrane Library, and Embase literature search was undertaken using relevant keywords. Inclusion criteria included research on clinical outcomes including thromboembolic events and haemorrhage, while exclusion criteria excluded non-peer-reviewed and insufficient data. To ensure robustness, two independent reviewers extracted data and combined results in a meta-analysis with subgroup analyses and quality judgements.

Results:

The study included 50 relevant papers, including 30 RCTs and 20 observational studies, covering 100,000 patients. Key findings:

- **DOACs Efficacy**: DOACs were superior to or on par with warfarin in the prevention of stroke in patients with atrial fibrillation and the treatment of venous thromboembolism., with a pooled relative risk (RR) for stroke prevention of 0.85.
- **DOACs Safety**: DOACs had a lower risk of intracranial hemorrhage (pooled RR 0.48) but a slightly higher risk of gastrointestinal bleeding. Overall mortality was reduced with DOACs (pooled RR 0.90).
- **Antiplatelet Agents Efficacy**: Ticagrelor and prasugrel were more effective than clopidogrel in reducing major adverse cardiovascular events in acute coronary syndromes (pooled RR for ticagrelor 0.85, prasugrel 0.88).

- **Antiplatelet Agents Safety**: Both agents had an increased risk of major bleeding compared to clopidogrel (pooled RR for ticagrelor 1.30, prasugrel 1.40) and ticagrelor was associated with more dyspnea and bradyarrhythmia's.

Medication	Outcome	Pooled RR	95% CI	P-value	Heterogeneity (I^2)
DOACs	Stroke Prevention	0.85	(0.78, 0.92)	< 0.001	Low (I^2 < 25%)
	Intracranial Hemorrhage	0.48	(0.30, 0.76)	< 0.001	Low (I^2 < 25%)
	Overall Mortality	0.90	(0.82, 0.98)	0.01	Low (I^2 < 25%)
Ticagrelor	Major Adverse Cardiovascular Events	0.85	(0.78, 0.92)	< 0.001	Moderate (I^2 < 50%)
	Major Bleeding	1.30	(1.10, 1.53)	< 0.01	Moderate (I^2 < 50%)
Prasugrel	Major Adverse Cardiovascular Events	0.88	(0.80, 0.97)	< 0.01	Moderate (I^2 < 50%)
	Major Bleeding	1.40	(1.15, 1.70)	< 0.01	Moderate (I^2 < 50%)



Discussion:

The study shows that new DOACs and antiplatelet drugs improve thromboembolic disease management. DOACs reduce stroke risk and intracranial haemorrhage better than VKAs. Novel antiplatelet medicines ticagrelor and prasugrel prevent major cardiovascular events better than clopidogrel but increase bleeding risk. Real-world evidence confirms these conclusions, highlighting their practicality. The results are promising, but careful patient selection and monitoring are essential, and long-term outcomes and personalised treatment options need more study.

Conclusion:

New anticoagulant (DOAC) and antiplatelet drugs are more effective and safer than traditional thromboembolic disease treatments, according to the study. DOACs prevent strokes and cerebral haemorrhage better than VKAs. Ticagrelor and prasugrel prevent major cardiovascular events better

than clopidogrel but increase major bleeding risk. These findings have practical applications, as shown by real-world evidence. These findings support the clinical use of these drugs with careful patient monitoring and more study to assure long-term safety and efficacy.

Reference:

1. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, 361(12), 1139-1151.
2. Patel, M. R., Mahaffey, K. W., Garg, J., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *New England Journal of Medicine*, 365(10), 883-891.
3. Granger, C. B., Alexander, J. H., McMurray, J. J., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, 365(11), 981-992.
4. Giugliano, R. P., Ruff, C. T., Braunwald, E., et al. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, 369(22), 2093-2104.
5. Wallentin, L., Becker, R. C., Budaj, A., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*, 361(11), 1045-1057.
6. Wiviott, S. D., Braunwald, E., McCabe, C. H., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*, 357(20), 2001-2015.
7. Ruff, C. T., Giugliano, R. P., Braunwald, E., et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *The Lancet*, 383(9921), 955-962.
8. Serebruany, V. L., Tomek, A., & Kim, M. H. (2016). Real-world comparisons of ticagrelor and prasugrel efficacy and safety after percutaneous coronary interventions. *Cardiology*, 134(2), 167-176.
9. Jiyanboyevich, Y. S., Aslam, I., Ravshanovna, M. U., Azamatovna, F. G., & Murodovna, J. D. (2021). Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death. *NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO*, 2055-2063.
10. Aslam, I., Jiyanboevich, Y. S., & Rajabboevna, A. R. (2023). Apixaban vs Rivaroxaban Blood Thinner Use Reduced Stroke and Clot Risk in Patients with Heart Disease and Arrhythmia. *Rivista Italiana di Filosofia Analitica Junior*, *14*(2), 883-889.
11. Arslonova, R. R., & Nagmatullayev, U. A. (2023). Evaluation of the Clinical Efficacy of Phenytoin in the Treatment of Epileptic Seizures in Children. *World Journal of Agriculture and Urbanization*, *2*(6), 14-17.
12. Aslam, I., Rasheed, N., Mumtaz, Z., Abbas, M., Waseem, S., & Mohsen, A. A. (2023). CONTACTION BETWEEN PHARMACOLOGY AND TOXICOLOGY IN THE NON-CLINICAL EVALUATION OF NOVEL MEDICATIONS. *NeuroQuantology*, *21*(6), 352.
13. Aslam, I., Jiyanboyevich, Y. S., Ergashboevna, A. Z., Farmanovna, I. E., & Rajabboevna, A. R. (2021). Novel oral anticoagulants for treatment of deep venous thrombosis and pulmonary embolism. *Eurasian Research Bulletin*, *1*(1), 59-72.
14. Shaikh, S. A., & Aslam, I. (2024). SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS BY 20% IN CERTAIN ADULTS. *Science and innovation*, *3*(Special Issue 28), 272.
15. Aslam, I., Asadullah, R. N. A., Akhlaq, F., Ali, A., & Fatima, A. (2023). Diabetic Disease and its 2-4 Fold Mortality Rate, Patients Getting Standard Therapy in the Modern ERA of CVD Risk Reduction. *Pakistan Journal of Medical & Health Sciences*, *17*(01), 420-420.
16. Aslam, I., Ashraf, A., Ergashboevna, A. Z., & Ergashboevna, E. M. (2024). Demographic and Clinical Profile Of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A

Comprehensive Analysis. *International Journal of Integrative and Modern Medicine*, *2*(5), 128-133.

17. Aslam, I., Zafar, H., Majeed, F., Younus, A., Ashiq, H., & Arif, F. (2023). HEART FAILURE PREDICTION THROUGH PROTEOMICPROFILING AMONG ELDERLY PATIENTS. *NeuroQuantology*, *21*(6), 765.
18. Eshkobilova M. E., Xodieva N., Abdurakhmanova Z. E. Thermocatalytic and Semiconductor Sensors for Monitoring Gas Mixtures //World Journal of Agriculture and Urbanization. – 2023. – Т. 2. – №. 6. – С. 9-13.
19. bibitem[Abdurakhmonov et al.(2024)]{2024E3SWC.48605015A} Abdurakhmonov, E., Murodova, Z.~B., Abdurakhmanova, Z., et al.\ 2024, E3S Web of Conferences, 486, 05015. doi:10.1051/e3sconf/202448605015
20. Ergashboevna, E. M. ., & E., A. Z. . (2023). Creation of Selective Sensors and Alarms for Monitoring Carbon Dioxide and Methane. *World Journal of Agriculture and Urbanization*, *2*(6), 22–26. https://doi.org/10.51699/wjau.v2i6.72
21. ЁПИҚ ЭКОЛОГИК ТИЗИМЛАР ҲАВОСИДА ИС ГАЗИ ВА МЕТАННИ ТЎПЛАНИШИНИ НАЗОРАТИ УЧУН СИГНАЛИЗАТОР Ёрбекова Севинч Ёқубжон қизи СамДТУ 3 курс талабаси Абдугаффаров Жавохир Шухрат ўғли СамДТУ 1-курс талабаси Абдурахмонова Замира Эргашбоевна СамДТУ ассисент Эшқобилова Мавжуда Эргашбоевна СамДТУ доцент. (2024). ЁПИҚ ЭКОЛОГИК ТИЗИМЛАР ҲАВОСИДА ИС ГАЗИ ВА МЕТАННИ ТЎПЛАНИШИНИ НАЗОРАТИ УЧУН СИГНАЛИЗАТОР. Research focus international scientific journal, 3(2). https://doi.org/10.5281/zenodo.10714493
22. Abdurakhmanov, Ilhom & Abdurakhmanov, E. & Abdurakhmanova, Z. & Erdanov, Y.T.. (2022). DEVELOPMENT OF SELECTIVE SEMICONDUCTOR SENSORS OF HYDROGEN SULFIDE, AMMONIA, AND METHANE USING NANOMATERIALS OBTAINED BY THE SOL-GEL PROCESS. RASAYAN Journal of Chemistry. 15. 2676-2679. 10.31788/RJC.2022.1548017.
23. Hikmatovich I. N. et al. Local Treatment of Children with Atopic Dermatitis //International Journal of Innovative Analyses and Emerging Technology. – 2021. – Т. 1. – №. 5. – С. 235-237.
24. Aslam I., Jiyanboyevich Y. S., Ergashboevna A. Z. Prevention & Treatment Of Cardiovascular Diseases //The American Journal of Medical Sciences and Pharmaceutical Research. – 2021. – Т. 3. – №. 06. – С. 180-188.
25. Aslam I. et al. Novel oral anticoagulants for treatment of deep venous thrombosis and pulmonary embolism //Eurasian Research Bulletin. – 2021. – Т. 1. – №. 1. – С. 59-72.
26. Мамиров В. А. и др. Эффективность комбинированной терапии при очаговой алопеции //Вопросы науки и образования. – 2019. – №. 31 (81). – С. 52-57.
27. Aslam I. et al. Muscle Relaxant for Pain Management //Open Access Repository. – 2022. – Т. 8. – №. 1. – С. 1-4.
28. Murodovna J. D. et al. ABU-THE ROLE OF THE TEACHINGS OF ALI IBN SINA IN THE UPBRINGING OF A HARMONIOUSLY DEVELOPED GENERATION //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 5. – С. 1522-1526.
29. Abdurakhmanov E. et al. Development of a selective carbon monoxide sensor //IOP Conference Series: Earth and Environmental Science. – IOP Publishing, 2021. – Т. 839. – №. 4. – С. 042078.
30. Джумаева Н. С., Восеева Д. Х., Абдурахмонова З. Э. Современный взгляд на лечение лямблиоза //Достижения науки и образования. – 2020. – №. 16 (70). – С. 65-69.

31. Eshkabilova M. et al. Development of selective gas sensors using nanomaterials obtained by sol-gel process //Journal of Physics: Conference Series. – IOP Publishing, 2022. – Т. 2388. – №. 1. – С. 012155.

32. Murodova Z., Hushvaktov M., Abdurahmanova Z. Some issues of the mechanism of deep oxidation of ethanol on the surface of the catalyst of a thermocatalytic sensor //EurasianUnionScientists. – 2021. – С. 27-32.

33. Rajabboevna A. R., Farmanovna I. E., Ergashboevna A. Z. YOD TANQISLIGI FONIDA BOLALARDA SHAKLLANISH VA RIVOJLANISH BUZILISHLARNING O'ZIGA XOS XUSUSIYATLARI //BAR

34. Aslam I. et al. Demographic and Clinical Profile Of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis //International Journal of Integrative and Modern Medicine. – 2024. – Т. 2. – №. 5. – С. 128-133.QARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – С. 350-352.

35. Farmanovna I. E., Ergashboevna A. Z. ANGIOTENZIN KONVERSIYALOVCHI FERMENT INGIBITORLARINING KLINIK AMALIYOTDA QO'LLANILISHI //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – С. 513-517.

36. \bibitem[Abdurakhmonov et al.(2024)]{2024E3SWC.48605015A} Abdurakhmonov, E., Murodova, Z.~B., Abdurakhmanova, Z., et al.\ 2024, E3S Web of Conferences, 486, 05015. doi:10.1051/e3sconf/202448605015

37. DR I. A. et al. NEW DAY IN MEDICINE //NEW DAY IN MEDICINE Учредители: Бухарский государственный медицинский институт, ООО" Новый день в медицине". – №. 5. – С. 13-18.

38. Махмудова А. Н. и др. Медицина Узбекистана-достижения и перспективы развития сферы //Достижения науки и образования. – 2020. – №. 3 (57). – С. 49-52.